Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer

Molecular Therapy

Volumn 19, Issue 4, 2011, Pages 650-657

  Li, Jun ^a   O'Malley, Mark ^a   Urban, Julie ^a   Sampath, Padma ^a,b   Guo, Z Sheng ^a   Kalinski, Pawel ^a,b   Thorne, Steve H ^a,b   Bartlett, David L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; RANTES; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CYTOTOXIC T LYMPHOCYTE; DRUG POTENTIATION; DRUG SAFETY; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SUBCUTANEOUS TISSUE TUMOR;

MUS; VACCINIA VIRUS;

EID: 79953327283     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.312     Document Type: Article

References (39)

1. Kloor, M (2009). Lymphocyte infiltration and prognosis in colorectal cancer. Lancet Oncol 10: 840-841.
2. Atreya, I and Neurath, MF (2008). Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies. Expert Rev Anticancer Ther 8: 561-572. (Pubitemid 351818351)
3. Laghi, L, Bianchi, P, Miranda, E, Balladore, E, Pacetti, V, Grizzi, F et al. (2009). CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 10: 877-884.
4. Harrop, R, Drury, N, Shingler, W, Chikoti, P, Redchenko, I, Carroll, MW et al. (2008). Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother 57: 977-986.
5. Kavanagh, B, Ko, A, Venook, A, Margolin, K, Zeh, H, Lotze, M et al. (2007). Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother 30: 762-772. (Pubitemid 47480759)
6. Alves, PM, Viatte, S, Fagerberg, T, Michielin, O, Bricard, G, Bouzourene, H et al. (2007). Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients. Cancer Immunol Immunother 56: 1795-1805. (Pubitemid 47313084)
7. McCart, JA, Ward, JM, Lee, J, Hu, Y, Alexander, HR, Libutti, SK et al. (2001). Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61: 8751-8757. (Pubitemid 34013887)
8. Guo, ZS, Naik, A, O'Malley, ME, Popovic, P, Demarco, R, Hu, Y et al. (2005). The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res 65: 9991-9998. (Pubitemid 41541480)
9. Kim, JH, Oh, JY, Park, BH, Lee, DE, Kim, JS, Park, HE et al. (2006). Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 14: 361-370. (Pubitemid 44184970)
10. Kirn, DH, Wang, Y, Le Boeuf, F, Bell, J and Thorne, SH (2007). Targeting of interferonbeta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 4: e353.
11. Thorne, SH, Hwang, TH, O'Gorman, WE, Bartlett, DL, Sei, S, Kanji, F et al. (2007). Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 117: 3350-3358. (Pubitemid 350096991)
12. Park, BH, Hwang, T, Liu, TC, Sze, DY, Kim, JS, Kwon, HC et al. (2008). Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 9: 533-542.
13. Levy, JA (2009). The unexpected pleiotropic activities of RANTES. J Immunol 182: 3945-3946.
14. Mueller, A and Strange, PG (2004). The chemokine receptor, CCR5. Int J Biochem Cell Biol 36: 35-38. (Pubitemid 37338472)
15. Mailliard, RB, Wankowicz-Kalinska, A, Cai, Q, Wesa, A, Hilkens, CM, Kapsenberg, ML et al. (2004). alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64: 5934-5937. (Pubitemid 39129387)
16. Lee, JJ, Foon, KA, Mailliard, RB, Muthuswamy, R and Kalinski, P (2008). Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J Leukoc Biol 84: 319-325. (Pubitemid 351960307)
17. Lu, PH and Negrin, RS (1994). A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153: 1687-1696. (Pubitemid 24251113)
18. Yurchenko, E, Tritt, M, Hay, V, Shevach, EM, Belkaid, Y and Piccirillo, CA (2006). CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence. J Exp Med 203: 2451-2460. (Pubitemid 44664615)
19. Tan, MC, Goedegebuure, PS, Belt, BA, Flaherty, B, Sankpal, N, Gillanders, WE et al. (2009). Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 182: 1746-1755.
20. Edinger, M, Cao, YA, Verneris, MR, Bachmann, MH, Contag, CH and Negrin, RS (2003). Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 101: 640-648. (Pubitemid 36077588)
21. Cao, YA, Bachmann, MH, Beilhack, A, Yang, Y, Tanaka, M, Swijnenburg, RJ et al. (2005). Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation. Transplantation 80: 134-139. (Pubitemid 40980907)
22. Karlsson, A, Giuriato, S, Tang, F, Fung-Weier, J, Levan, G and Felsher, DW (2003). Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 101: 2797-2803. (Pubitemid 36857646)
23. Thorne, SH, Negrin, RS and Contag, CH (2006). Synergistic antitumor effects of immune cell-viral biotherapy. Science 311: 1780-1784.
24. Dudley, ME and Rosenberg, SA (2007). Adoptive cell transfer therapy. Semin Oncol 34: 524-531. (Pubitemid 350236303)
25. Watchmaker, PB, Berk, E, Muthuswamy, R, Mailliard, RB, Urban, JA, Kirkwood, JM et al. (2010). Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells. J Immunol 184: 591-597.
26. Thorne, SH, Liang, W, Sampath, P, Schmidt, T, Sikorski, R, Beilhack, A et al. (2010). Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy. Mol Ther 18: 1698-1705.
27. Kumar, S, Gao, L, Yeagy, B and Reid, T (2008). Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 10: 371-379.
28. Galanis, E, Okuno, SH, Nascimento, AG, Lewis, BD, Lee, RA, Oliveira, AM et al. (2005). Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther 12: 437-445. (Pubitemid 40394296)
29. Post, DE, Fulci, G, Chiocca, EA and Van Meir, EG (2004). Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther 4: 41-51. (Pubitemid 38854945)
30. Yu, DC, Chen, Y, Dilley, J, Li, Y, Embry, M, Zhang, H et al. (2001). Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 61: 517-525. (Pubitemid 32128610)
31. Twigger, K, Vidal, L, White, CL, De Bono, JS, Bhide, S, Coffey, M et al. (2008). Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res 14: 912-923. (Pubitemid 351231176)
32. Cole, C, Qiao, J, Kottke, T, Diaz, RM, Ahmed, A, Sanchez-Perez, L et al. (2005). Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat Med 11: 1073-1081. (Pubitemid 41486829)
33. Kirn, DH and Thorne, SH (2009). Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 9: 64-71.
34. Banaszynski, LA, Sellmyer, MA, Contag, CH, Wandless, TJ and Thorne, SH (2008). Chemical control of protein stability and function in living mice. Nat Med 14: 1123-1127.
35. Bahar, MW, Kenyon, JC, Putz, MM, Abrescia, NG, Pease, JE, Wise, EL et al. (2008). Structure and function of A41, a vaccinia virus chemokine binding protein. PLoS Pathog 4: e5.
36. Lapteva, N, Aldrich, M, Weksberg, D, Rollins, L, Goltsova, T, Chen, SY et al. (2009). Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother 32: 145-156.
37. Leemhuis, T, Wells, S, Scheffold, C, Edinger, M and Negrin, RS (2005). A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11: 181-187. (Pubitemid 40287916)
38. Sasaki, A, Melder, RJ, Whiteside, TL, Herberman, RB and Jain, RK (1991). Preferential localization of human adherent lymphokine-activated killer cells in tumor microcirculation. J Natl Cancer Inst 83: 433-437.
39. Giermasz, AS, Urban, JA, Nakamura, Y, Watchmaker, P, Cumberland, RL, Gooding, W et al. (2009). Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother 58: 1329-1336.